Astrana Health (NASDAQ:ASTH) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Astrana Health (NASDAQ:ASTH) had its price objective raised by research analysts at Needham & Company LLC from $41.00 to $45.00 in a research note issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC‘s price target would indicate a potential upside of 15.36% from the company’s current price.

Several other equities research analysts also recently commented on ASTH. Truist Financial upped their price target on shares of Astrana Health from $47.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Astrana Health in a research note on Thursday, August 27th. Wall Street Zen cut shares of Astrana Health from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Oppenheimer assumed coverage on shares of Astrana Health in a research note on Tuesday, September 15th. They set an “outperform” rating and a $53.00 target price on the stock. Finally, TD Cowen increased their target price on Astrana Health from $45.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Astrana Health currently has a consensus rating of “Moderate Buy” and an average price target of $50.38.

Astrana Health Price Performance

ASTH stock opened at $39.01 on Friday. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 1.05. Astrana Health has a one year low of $18.08 and a one year high of $51.60. The firm has a market capitalization of $2.17 billion, a PE ratio of 47.57 and a beta of 1.18. The firm has a 50-day moving average of $37.06 and a two-hundred day moving average of $33.98.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Thursday, November 5th. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.46 by $0.25. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Astrana Health had a net margin of 1.05% and a return on equity of 10.30%. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period last year, the company posted $0.01 earnings per share. On average, analysts forecast that Astrana Health will post 1.36 earnings per share for the current year.

Institutional Trading of Astrana Health

Several institutional investors have recently made changes to their positions in the stock. Maryland State Retirement & Pension System grew its position in Astrana Health by 50.7% during the third quarter. Maryland State Retirement & Pension System now owns 9,303 shares of the company’s stock valued at $331,000 after purchasing an additional 3,129 shares in the last quarter. Penn Capital Management Company LLC increased its stake in Astrana Health by 13.9% in the 3rd quarter. Penn Capital Management Company LLC now owns 19,565 shares of the company’s stock valued at $696,000 after buying an additional 2,388 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in Astrana Health by 19.3% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 13,600 shares of the company’s stock worth $484,000 after buying an additional 2,200 shares in the last quarter. Simplicity Wealth LLC purchased a new stake in Astrana Health in the 3rd quarter worth approximately $296,000. Finally, Sterling Capital Management LLC boosted its stake in shares of Astrana Health by 17.2% during the 3rd quarter. Sterling Capital Management LLC now owns 9,269 shares of the company’s stock valued at $330,000 after buying an additional 1,359 shares during the period. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Key Astrana Health News

Here are the key news stories impacting Astrana Health this week:

• Positive Sentiment: Third-quarter revenue was $1.02 billion, in line with consensus and up 7.1% from a year earlier. Earnings improved substantially from the year-ago quarter. Astrana Health Q3 Revenue Tops $1 Billion as Profit Surges
• Neutral Sentiment: EPS coverage is inconsistent: one report gives $0.71 per share, above its cited $0.46 consensus, while Zacks reports $0.26 per share against a $0.44 estimate. The figures may reflect different earnings measures or estimates, making the headline earnings comparison less clear. Astrana Health Q3 Earnings Lag Estimates
• Negative Sentiment: Despite the solid quarter, the company’s quarterly revenue guidance reportedly fell short of expectations. That weaker forward outlook is a likely source of investor concern and could outweigh the in-line revenue result. Q3 in line, but quarterly revenue guidance misses expectations

About Astrana Health

Astrana Health, Inc (NASDAQ: ASTH), formerly known as Apollo Medical Holdings, is a healthcare enablement company focused on helping providers and health plans deliver coordinated, value-based care. The company combines physician networks, care-management capabilities, technology and data analytics to support improved clinical outcomes and more efficient healthcare delivery.

Astrana Health’s services include population health management, physician practice support, utilization management, care coordination and clinical analytics.